Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Cancer Biol Med
2018 May 01;152:178-181. doi: 10.20892/j.issn.2095-3941.2018.0003.
Show Gene links
Show Anatomy links
Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report.
Zhang L
,
Li Y
,
Zhang S
,
Gao C
,
Nie K
,
Ji Y
.
???displayArticle.abstract???
Crizotinib, a small molecular tyrosine kinase inhibitor, manifests dramatic responses in patients with non-small cell lung cancer with echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) rearrangements. ALK gene point mutation is the primary mechanism of acquired crizotinib resistance; however, the intrinsic mechanism is not fully understood. Here, we report a patient with a low mutant allele fraction (MAF) of EML4-ALK rearrangement, who experienced primary resistance to crizotinib treatment. The patient was a 66-year-old Chinese man, who had a history of metastatic lung cancer and was treated with first- and third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs). After 14 months of osimertinib treatment, his disease progressed, and next-generation sequencing was performed from a liquid biopsy of the patient's blood. An EML4-ALK rearrangement was found and crizotinib was administered. The patient's lung lesions continued to progress after one month of crizotinib treatment, and pemetrexed-bevacizumab was initiated. After two cycles of chemotherapy, the metastatic cancers shrunk, and the patient maintained stable disease at his last follow-up. EML4-ALK rearrangements can happen in patients with EGFR-positive NSCLC, after acquired resistance to EGFR TKI treatment. The EGFR T790M and C797G mutations occur in cis is a critical mechanism of resistance to osimertinib therapy. The MAF of EML4-ALK rearrangements in cancer cells might be a predictive factor for crizotinib treatment.
Bae,
EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
2007, Pubmed
Bae,
EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
2007,
Pubmed
Bell,
Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms.
2008,
Pubmed
Chen,
Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer.
2018,
Pubmed
Chen,
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
2015,
Pubmed
Crystal,
New targets in advanced NSCLC: EML4-ALK.
2011,
Pubmed
Doebele,
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
2012,
Pubmed
Dong,
EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer.
2017,
Pubmed
Dy,
Angiogenesis inhibitors in lung cancer: a promise fulfilled.
2006,
Pubmed
Horn,
Angiogenesis in the treatment of non-small cell lung cancer.
2009,
Pubmed
Jänne,
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
2015,
Pubmed
Kobayashi,
An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.
2005,
Pubmed
Ku,
Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials.
2011,
Pubmed
Li,
Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors.
2011,
Pubmed
,
Echinobase
Ou,
Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.
2017,
Pubmed
Oztan,
Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib.
2017,
Pubmed
Pan,
[Epidermal growth factor receptor mutation in Chinese patients with non-small cell lung cancer].
2005,
Pubmed
Rossi,
Angiogenesis inhibitors and vascular disrupting agents in non-small cell lung cancer.
2009,
Pubmed
Russo,
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going.
2017,
Pubmed
Shaw,
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
2014,
Pubmed
Shaw,
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
2011,
Pubmed
Shaw,
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
2013,
Pubmed
Solomon,
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.
2016,
Pubmed
Suda,
EGFR T790M mutation: a double role in lung cancer cell survival?
2009,
Pubmed
Tang,
Increased Expression of IRE1α Associates with the Resistant Mechanism of Osimertinib (AZD9291)-resistant non-small Cell Lung Cancer HCC827/OSIR Cells.
2018,
Pubmed
Van Dyke,
COX-2/EGFR expression and survival among women with adenocarcinoma of the lung.
2008,
Pubmed
Wang,
Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance.
2017,
Pubmed
Wong,
The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.
2009,
Pubmed
,
Echinobase
Yu,
Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.
2007,
Pubmed
Zhang,
Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.
2010,
Pubmed
Zhang,
PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance.
2017,
Pubmed
